DYN Articles, Dyne Therapeutics Inc. - From 03/25/24

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Shares of Aehr Test Systems (NASDAQ: AEHR) fell sharply duri...

- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25,...

Cantor Fitzgerald has initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA), noting the company has the complete package, inclu...

WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adv...

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. (NYSE: COO) rose sharply du...

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in th...

- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the P...

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advan...

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...